BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control.
Tuesday, 9 March 2021
BioLargo, Inc. Discusses Commercial PFAS Treatment Trials and Garratt-Callahan Partnership with The Stock Day Podcast
Phoenix, AZ -- March 09, 2021 -- The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB:BLGO), a company thatinvents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, air quality control, and infection control. President and CEO of BioLargo, Dennis P. Calvert, joined Stock Day host Everett Jolly.
Jolly began the interview by asking about BioLargo's current projects. "This is a company that's done the work to prove out technical innovations," said Calvert. "We focus on clean air, clean water, and a clean Earth, so we're an environmental engineering group, and we have incredible innovations that are finding their way to market," he continued. "We're really a sustainable solutions provider."
"Please give my listeners an update on your PFAS solution. Does it really work, how big is it, and what is the opportunity going forward?", asked Jolly. "The Biden Administration has really made this a priority," explained Calvert, adding that PFAS can be found in our water, bodies, and products. "It has been linked to adverse health effects."
"We started on PFAS about a year and a half to two years ago, and we are now building our first commercial units. We have four commercial trials, two are confirmed and two are in the works," shared Calvert. "This is big business."
Jolly then asked about the company's balance sheet improvements over the past two to three quarters, specifically related to the reduction of debt obligations. "We have this depth of talent that would rival the largest companies in the world," said Calvert. "We took some risks, we brought in a lot of money, we had some debt, it was expensive," he continued. "Now that's coming to an end," said Calvert. "A very small number will come due in August, it's convertible," he explained. "All in, it was about $5 million, and we're down to about $400,000 [in corporate debt obligations]," Calvert added. "The future is so bright, the commercial opportunities are so expansive, and the innovations are the real deal."
The conversation then turned to the Company's Garratt-Callahan partnership. "First of all, this is just a wonderful company. They're a hundred plus years old, they are a national player, and they have a huge sales force," said Calvert. Added Calvert, "Since the inception, we thought [the relationship] would expand beyond the initial focus and it has. We're already working on some projects with some of their clients, and that is the start of something that could be really great."
"Why should investors take a look at BioLargo?", asked Jolly. Calvert responded, "The things we are doing are massive, and the technology is proven. Now we get to enjoy the adoption cycle. This is a company that is highly committed to investing in the business, deferring [management] compensation, and making sure that this company has the right people and the tools to go out and do something extraordinarily special. Everything we are doing we believe is number one in its category."
BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website atwww.BioLargo.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
About The "Stock Day" Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.